SRPT - Sarepta Therapeutics, Inc.

QQQ $ 435.98 $ 8.58 (2.01 %)

DIA $ 386.87 $ 4.54 (1.19 %)

SPY $ 511.25 $ 6.26 (1.24 %)

TLT $ 89.88 $ 0.90 (1.01 %)

GLD $ 212.97 $ -0.17 (-0.08 %)

Previous Close

$ 133.66

Open

$ 132.03

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 131.24 - $ 134.44

52 Week Range

$ 55.25 - $ 159.89

Volume

1,196,284

Average Volume

Market Cap

13.25B

Beta (5Y Monthly)

$ 0.80

PE Ratio (TTM)

$ 784.02

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-01-2024	03-31-2024	10-Q
2	02-28-2024	12-31-2023	10-K
3	11-01-2023	09-30-2023	10-Q
4	08-02-2023	06-30-2023	10-Q
5	05-02-2023	03-31-2023	10-Q
6	02-28-2023	12-31-2022	10-K
7	11-02-2022	09-30-2022	10-Q
8	08-02-2022	06-30-2022	10-Q
9	05-04-2022	03-31-2022	10-Q
10	03-01-2022	12-31-2021	10-K
11	11-03-2021	09-30-2021	10-Q
12	08-04-2021	06-30-2021	10-Q
13	05-05-2021	03-31-2021	10-Q
14	03-01-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-05-2020	06-30-2020	10-Q
17	05-06-2020	03-31-2020	10-Q
18	02-26-2020	12-31-2019	10-K
19	11-07-2019	09-30-2019	10-Q
20	08-07-2019	06-30-2019	10-Q
21	05-08-2019	03-31-2019	10-Q
22	02-28-2019	12-31-2018	10-K
23	10-31-2018	09-30-2018	10-Q
24	08-08-2018	06-30-2018	10-Q
25	05-03-2018	03-31-2018	10-Q
26	03-01-2018	12-31-2017	10-K
27	11-01-2017	09-30-2017	10-Q
28	08-03-2017	06-30-2017	10-Q
29	05-04-2017	03-31-2017	10-Q
30	02-28-2017	12-31-2016	10-K
31	11-07-2016	09-30-2016	10-Q
32	08-09-2016	06-30-2016	10-Q
33	05-05-2016	03-31-2016	10-Q
34	02-25-2016	12-31-2015	10-K
35	11-05-2015	09-30-2015	10-Q
36	08-06-2015	06-30-2015	10-Q
37	05-07-2015	03-31-2015	10-Q
38	02-26-2015	12-31-2014	10-K
39	11-06-2014	09-30-2014	10-Q
40	08-07-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

JP Morgan Maintains Overweight on Sarepta ...
05/03/2024 18:52:25

JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and lowers the price target fro...

What Analysts Are Saying About Sarepta The...
05/02/2024 21:00:45

Cantor Fitzgerald Reiterates Neutral on Sa...
05/02/2024 16:13:11

Cantor Fitzgerald analyst Kristen Kluska reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and maintains $128 pri...

Needham Reiterates Buy on Sarepta Therapeu...
05/02/2024 10:51:16

Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and maintains $166 price target.

apple-kellanova-and-3-stocks-to-watch-heading-into-thursday

Apple, Kellanova And 3 Stocks To Watch Hea...
05/02/2024 06:25:22

Sarepta Therapeutics Q1 2024 Adj EPS $0.73...
05/01/2024 20:25:01

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.73 per share which beat the analyst consensus estimate of ...

10-health-care-stocks-whale-activity-in-todays-session

10 Health Care Stocks Whale Activity In To...
04/04/2024 17:35:24

this-gene-therapy-player-duchenne-data-is-impressive-analyst-upgrades-regenxbio

This Gene Therapy Player Duchenne Data Is ...
03/08/2024 18:43:05

REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 t...

UBS Maintains Buy on Sarepta Therapeutics,...
03/01/2024 16:48:39

UBS analyst Colin Bristow maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $164 to $...

Cantor Fitzgerald Reiterates Neutral on Sa...
02/29/2024 18:38:23

Cantor Fitzgerald analyst Kristen Kluska reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and maintains $128 pri...

RBC Capital Maintains Outperform on Sarept...
02/29/2024 17:49:36

RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price targe...

Citigroup Maintains Buy on Sarepta Therape...
02/29/2024 17:09:13

Citigroup analyst David Hoang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $160 ...

Barclays Maintains Overweight on Sarepta T...
02/29/2024 13:31:38

Barclays analyst Gena Wang maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Overweight and raises the price target from $...

Needham Maintains Buy on Sarepta Therapeut...
02/29/2024 12:53:16

Needham analyst Gil Blum maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and lowers the price target from $169 to $166.

Sarepta Therapeutics: Q4 Earnings Insights
02/28/2024 21:15:15

Sarepta Therapeutics Q4 2023 Adj EPS $0.82...
02/28/2024 21:13:53

Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly earnings of $0.82 per share which beat the analyst consensus estimate of ...

Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

A Preview Of Sarepta Therapeutics's Earnings
02/27/2024 18:01:45

median-drug-prices-for-rare-diseases-hit-300k-in-2023-report-highlights-lack-of-clear-rationale-behind-escalating-drug-prices

Median Drug Prices For Rare Diseases Hit $...
02/26/2024 17:14:35

Latest pharmaceutical trends in the U.S. as drug prices surged 35% in 2023. Uncover insights into the industry's focus on r...

Wedbush Reiterates Outperform on Sarepta T...
02/20/2024 13:52:04

Wedbush analyst Andreas Argyrides reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $224 price t...

6 Gene Therapy M&A Targets On The Radar
03/27/2019 16:45:40